Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02807272

Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia — CMML/AML  

Leukemia, Myelomonocytic, Chronic Clinical Trial

Official title:
A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other Myelodysplastic /Myeloproliferative Neoplasias, and Acute Myeloid Leukemia

Clinical Trial Summary

A Phase 2 study to investigate the antitumor activity in terms of overall response rate (ORR) of tipifarnib in approximately 36 eligible subjects with Myelodysplastic/Myeloproliferative Neoplasias (MDS/MPN), including Chronic Myelomonocytic Leukemia (CMML), and 36 eligible subjects with Acute Myeloid Leukemia (AML). Subjects (amendment 3 Cohorts 1-4) will receive tipifarnib administered at a dose of 400 mg, orally with food, twice a day (bid) for 21 days in 28 day cycles.

Clinical Trial Description

This Phase 2 study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with Myelodysplastic/Myeloproliferative Neoplasias (MDS/MPN cohorts) and Acute Myeloid Leukemia (AML cohorts). For MDS/MPN cohorts, this study will assess the antitumor activity of tipifarnib, in terms of ORR, in subjects with MDS/MPN, including CMML, who have a high ratio of expression of CXCR4 to CXCR2 (CXCR4/2 ratio) in their bone marrow and in those with a low CXCR4/2 ratio. For AML cohorts, this study will assess the antitumor activity of tipifarnib, in terms of ORR, in subjects with AML who have a high ratio of expression of CXCR4 to CXCR2 (CXCR4/2 ratio) in their bone marrow and in those with low CXCR4/2 ratio. Subjects enrolled in the study will consist of patients with KRAS, NRAS wild type status. 1. Subjects with MDS/MPN with high CXCR4/2 ratio 2. Subjects with MDS/MPN with low CXCR4/2 ratio 3. Subjects with AML with high CXCR4/2 ratio 4. Subjects with AML with low CXCR4/2 ratio ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02807272
Study type Interventional
Source Kura Oncology, Inc.
Contact
Status Completed
Phase Phase 2
Start date October 2016
Completion date December 14, 2020
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02841540 - A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes Phase 1
Completed NCT01464047 - Korean Post-marketing Surveillance for Sprycel® N/A
Terminated NCT01957644 - Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML Phase 1
Active, not recruiting NCT03268954 - Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Phase 3
Completed NCT00255346 - Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Phase 2
Withdrawn NCT04264806 - A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) Phase 2
Completed NCT02472691 - Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT Phase 2
Terminated NCT00109538 - Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) Phase 3
Completed NCT00025662 - Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS Phase 2
Completed NCT02891551 - An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands
Terminated NCT00510289 - Sorafenib in Myelodysplastic Syndrome Phase 2
Completed NCT03814005 - A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems Phase 1
Completed NCT00744536 - Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS Phase 2
Completed NCT02907359 - Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Phase 3
Completed NCT01519011 - Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine Phase 1
Completed NCT05218902 - A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Terminated NCT03175978 - IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome Phase 1/Phase 2
Recruiting NCT03040401 - A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) Phase 1/Phase 2
Recruiting NCT05201066 - Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. Phase 2
Active, not recruiting NCT05883956 - A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia Phase 3